Agreed - this is a development stage biotech. Anyone knows ratings should be based on pipeline prospects, not p/e. It may be that those prospects are getting so close that other forces have decided it's time to accumulate and The Street is not exactly what could be termed a reputable player in this regard. Buy on the dips here. That's my plan.